DOACs Linked to Lower Stroke and Bleeding in Elderly AF
This decade-long nationwide cohort provides real-world outcome data on DOAC, warfarin, and no-anticoagulation strategies in AF patients aged 75 and older, a population underrepresented in pivotal trials.
📅 Journal publication: Aug 18, 2026·Last updated: Aug 22, 2026
DOACs safely reduce stroke risk in elderly AF patients.
Direct oral anticoagulants (DOACs) are increasingly used in elderly patients with atrial fibrillation (AF), offering a safer alternative to warfarin. DOACs were associated with reduced stroke and gastrointestinal bleeding (GIB) risks compared to non-users: stroke risk reduced by 29% and GIB by 19%. The study confirms DOACs as a safer option than warfarin in elderly AF patients, reducing stroke and gastrointestinal bleeding risks without increasing intracranial hemorrhage (ICH) risk. DOACs are a safer, effective option for managing atrial fibrillation in elderly patients.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.